Drug delivery after biodegradation of the stent scaffolding

Abstract

Disclosed herein is a stent comprising: a bioabsorbable polymeric scaffolding; and a coating comprising a bioabsorbable material on at least a portion of the scaffolding, wherein the degradation rate of all or substantially all of the bioabsorbable polymer of the scaffolding is faster than the degradation rate of all or substantially all of the bioabsorbable material of the coating.

1 . A stent comprising:
 a bioabsorbable polymeric scaffolding; and   a coating comprising a bioabsorbable material on at least a portion of the scaffolding, wherein the degradation rate of all or substantially all of the bioabsorbable polymer of the scaffolding is faster than the degradation rate of all or substantially all of the bioabsorbable material of the coating.   
   
   
       2 . The stent according to  claim 1 , wherein the stent includes an anti-proliferative agent, an anti-inflammatory agent, or a mixture thereof. 
   
   
       3 . The stent according to  claim 2 , wherein the anti-proliferative agent is selected from the group consisting of Everolimus, Rapamycin, and/or derivatives thereof. 
   
   
       4 . The stent according to  claim 2 , wherein the anti-inflammatory agent is Clobetasol. 
   
   
       5 . The stent according to  claim 1 , wherein the coating material comprises Everolimus and poly(D,L-lactide) of a 1:1 ratio, and the scaffolding comprises D,L-lactide and glycolide monomers of a 1:9 ratio. 
   
   
       6 . A method treating a body lumen, the method comprising:
 providing a stent comprising a scaffolding that degrades at a faster rate than a coating on the scaffolding; and   deploying the stent at a treatment area in a body lumen.   
   
   
       7 . The method according to  claim 6 , wherein the stent includes an anti-proliferative agent, an anti-inflammatory agent, or a mixture thereof. 
   
   
       8 . The method according to  claim 6 , wherein an anti-inflammatory agent is mixed or dispersed within the scaffolding. 
   
   
       9 . The method according to  claim 6 , wherein an anti-inflammatory agent and the anti-proliferative agent is delivered from at least a portion of the coating. 
   
   
       10 . The method according to  claim 6 , wherein an anti-inflammatory agent is delivered from the scaffolding and suppresses inflammation of the lumen during all or a majority of the degradation of the scaffolding. 
   
   
       11 . The method according to  claim 6 , wherein the coating in the stent comprises Everolimus and poly(D,L-lactide) of a 1:1 ratio, and the scaffolding comprises D,L-lactide and glycolide monomers of a 1:9 ratio. 
   
   
       12 . The method according to  claim 6 , wherein the stent includes Everolimus, Rapamycin, and/or derivatives thereof. 
   
   
       13 . The method according to  claim 6 , wherein the stent includes Clobetasol. 
   
   
       14 . The method according to  claim 6 , wherein upon deployment of the stent in the treatment area, the scaffolding substantially or completely degrades from the treatment area before the coating substantially or completely degrades. 
   
   
       15 . The method according to  claim 6 , wherein the coating delivers a drug to the lumen during degradation of the scaffolding and after substantial or complete degradation of the scaffolding. 
   
   
       16 . The method according to  claim 6 , wherein the coating becomes endothelialized in a wall of the lumen and delivers a drug after the scaffolding has substantially or completely degraded. 
   
   
       17 . A method of treating a body lumen, the method comprising:
 deploying a first stent at a treatment area, wherein the first stent includes a bioabsorbable polymeric scaffolding and a coating having a bioabsorbable material on at least a portion of the scaffolding, and wherein the degradation rate of all or substantially all of the bioabsorbable polymer of the scaffolding is faster than the degradation rate of all or substantially all of the bioabsorbable material of the coating; and   deploying a second stent in at least a portion of the treatment area.   
   
   
       18 . The method according to  claim 17 , wherein an anti-inflammatory agent is mixed or dispersed within the scaffolding. 
   
   
       19 . The method according to  claim 17 , wherein an anti-inflammatory agent is delivered from at least a portion of the coating material of the first stent, wherein the coating material comprises an anti-proliferative agent. 
   
   
       20 . The method according to  claim 17 , wherein an anti-inflammatory agent is delivered from the scaffolding of the first stent and suppresses inflammation of the body lumen during substantial or complete degradation of the scaffolding. 
   
   
       21 . The method according to  claim 17 , wherein the stent includes an anti-proliferative agent. 
   
   
       22 . The method according to  claim 21 , wherein the anti-proliferative agent in the first stent is Everolimus, Rapamycin, and/or derivatives thereof. 
   
   
       23 . The method according to  claim 17 , wherein the first stent includes an anti-inflammatory agent. 
   
   
       24 . The method according to  claim 23 , wherein the anti-inflammatory agent in the first stent is Clobetasol. 
   
   
       25 . The method according to  claim 17 , wherein the coating material in the first stent comprises Everolimus and poly(D,L-lactide) of a 1:1 ratio, and the scaffolding comprises D,L-lactide and glycolide monomers of a 1:9 ratio. 
   
   
       26 . The method according to  claim 17 , wherein the second stent is deployed when the scaffolding has substantially or completely degraded. 
   
   
       27 . The method according to  claim 17 , wherein the coating material of the first stent is capable of at least partially eluting a drug when the second stent is deployed. 
   
   
       28 . The method according to  claim 17 , wherein the first stent includes Everolimus, Rapamycin, and/or derivatives thereof. 
   
   
       29 . The method according to  claim 17 , wherein the first stent includes Clobetasol. 
   
   
       30 . The method according to  claim 17 , wherein upon deployment of the stent in the treatment area, the scaffolding substantially or completely degrades from the treatment area before the coating substantially or completely degrades. 
   
   
       31 . The method according to  claim 17 , wherein the coating delivers a drug to the lumen during degradation of the scaffolding and after substantial or complete degradation of the scaffolding. 
   
   
       32 . The method according to  claim 17 , wherein the coating becomes endothelialized in a wall of the lumen and delivers a drug after the scaffolding has substantially or completely degraded.